Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
10 2020
Historique:
received: 27 11 2019
accepted: 07 07 2020
pubmed: 5 8 2020
medline: 15 12 2020
entrez: 5 8 2020
Statut: ppublish

Résumé

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer

Identifiants

pubmed: 32747829
doi: 10.1038/s41591-020-1008-z
pii: 10.1038/s41591-020-1008-z
pmc: PMC8381722
mid: NIHMS1715889
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1549-1556

Subventions

Organisme : Blood Cancer UK
ID : 13042
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : ErratumIn

Références

Cell Rep. 2019 Jul 30;28(5):1370-1384.e5
pubmed: 31365877
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Blood. 2019 Mar 7;133(10):1096-1107
pubmed: 30670446
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873
pubmed: 27100738
Bioinformatics. 2009 Nov 1;25(21):2865-71
pubmed: 19561018
Leukemia. 2016 Mar;30(3):666-73
pubmed: 26514544
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
J Mol Cell Biol. 2019 Jul 19;11(7):524-530
pubmed: 30925588
Am J Pathol. 1994 Aug;145(2):338-44
pubmed: 8053492
Cancer Epidemiol. 2016 Jun;42:186-98
pubmed: 27090942
Int J Epidemiol. 2018 Jun 1;47(3):700-700g
pubmed: 29618056
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
J Clin Oncol. 2011 May 20;29(15):1971-9
pubmed: 21519010
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Cancer Discov. 2019 Jul;9(7):962-979
pubmed: 31068365
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Leukemia. 2016 Aug;30(8):1793-5
pubmed: 27125205
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Blood. 2017 Apr 27;129(17):2347-2358
pubmed: 28223278
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Science. 2019 Aug 9;365(6453):599-604
pubmed: 31395785
Blood. 2011 Dec 8;118(24):6239-46
pubmed: 21998214
Hum Mutat. 2016 Sep;37(9):865-76
pubmed: 27328919
N Engl J Med. 2018 Oct 11;379(15):1416-1430
pubmed: 30304655
Cell. 2004 Dec 17;119(6):847-60
pubmed: 15607980
N Engl J Med. 2011 Jun 30;364(26):2496-506
pubmed: 21714648
Leukemia. 2019 Jul;33(7):1747-1758
pubmed: 30635634
J Clin Oncol. 2012 Mar 10;30(8):820-9
pubmed: 22331955
J Clin Oncol. 2008 Oct 10;26(29):4791-7
pubmed: 18695255
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Cell. 2004 Dec 17;119(6):861-72
pubmed: 15607981
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Blood. 2012 Mar 1;119(9):2114-21
pubmed: 22186996
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699
pubmed: 24030381
Nat Genet. 2018 Oct;50(10):1381-1387
pubmed: 30224644
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Blood Adv. 2020 Feb 11;4(3):482-495
pubmed: 32027746
Cancer Discov. 2018 Feb;8(2):174-183
pubmed: 29247016

Auteurs

Elsa Bernard (E)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Robert P Hasserjian (RP)

Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

Sean M Devlin (SM)

Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Juan S Medina-Martinez (JS)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Tetsuichi Yoshizato (T)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Yusuke Shiozawa (Y)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Ryunosuke Saiki (R)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Luca Malcovati (L)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Department of Hematology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy.

Max F Levine (MF)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Juan E Arango (JE)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Yangyu Zhou (Y)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Francesc Solé (F)

MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain.

Catherine A Cargo (CA)

Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.

Detlef Haase (D)

Clinics of Hematology and Medical Oncology, University Medical Center, Göttingen, Germany.

Maria Creignou (M)

Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Ulrich Germing (U)

Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.

Yanming Zhang (Y)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Gunes Gundem (G)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Araxe Sarian (A)

Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Arjan A van de Loosdrecht (AA)

Department of Hematology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands.

Martin Jädersten (M)

Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Magnus Tobiasson (M)

Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Olivier Kosmider (O)

Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin and Université de Paris, Université Paris Descartes, Paris, France.

Matilde Y Follo (MY)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Felicitas Thol (F)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Hannover, Germany.

Ronald F Pinheiro (RF)

Drug Research and Development Center, Federal University of Ceara, Ceara, Brazil.

Valeria Santini (V)

MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy.

Ioannis Kotsianidis (I)

Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.

Jacqueline Boultwood (J)

Radcliffe Department of Medicine, University of Oxford and Oxford BRC Haematology Theme, Oxford, UK.

Fabio P S Santos (FPS)

Oncology-Hematology Center, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Julie Schanz (J)

Clinics of Hematology and Medical Oncology, University Medical Center, Göttingen, Germany.

Senji Kasahara (S)

Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.

Takayuki Ishikawa (T)

Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.

Hisashi Tsurumi (H)

Department of Hematology, Gifu University Graduate School of Medicine, Gifu, Japan.

Akifumi Takaori-Kondo (A)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Toru Kiguchi (T)

Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan.

Chantana Polprasert (C)

Department of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

John M Bennett (JM)

Lab. Medicine and Pathology, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.

Virginia M Klimek (VM)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Michael R Savona (MR)

Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

Monika Belickova (M)

Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

Christina Ganster (C)

Clinics of Hematology and Medical Oncology, University Medical Center, Göttingen, Germany.

Laura Palomo (L)

MDS Group, Institut de Recerca Contra la Leucèmia Josep Carreras, Barcelona, Spain.

Guillermo Sanz (G)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.

Lionel Ades (L)

Department of Hematology, Hôpital St Louis and Paris University, Paris, France.

Matteo Giovanni Della Porta (MG)

Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Harold K Elias (HK)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alexandra G Smith (AG)

Department of Health Sciences, University of York, York, UK.

Yesenia Werner (Y)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Minal Patel (M)

Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Agnès Viale (A)

Integrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Katelynd Vanness (K)

Integrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Donna S Neuberg (DS)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Kristen E Stevenson (KE)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Kamal Menghrajani (K)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kelly L Bolton (KL)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Pierre Fenaux (P)

Department of Hematology, Hôpital St Louis and Paris University, Paris, France.

Andrea Pellagatti (A)

Radcliffe Department of Medicine, University of Oxford and Oxford BRC Haematology Theme, Oxford, UK.

Uwe Platzbecker (U)

Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University of Leipzig, Leipzig, Germany.

Michael Heuser (M)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School, Hannover, Germany.

Peter Valent (P)

Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.

Shigeru Chiba (S)

Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Yasushi Miyazaki (Y)

Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Carlo Finelli (C)

Institute of Hematology, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Maria Teresa Voso (MT)

MDS Cooperative Group GROM-L, Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.

Lee-Yung Shih (LY)

Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan City, Taiwan.

Michaela Fontenay (M)

Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin and Université de Paris, Université Paris Descartes, Paris, France.

Joop H Jansen (JH)

Laboratory Hematology, Department LABGK, Radboud University Medical Centre, Nijmegen, the Netherlands.

José Cervera (J)

Department of Hematology and Genetics Unit, University Hospital La Fe, Valencia, Spain.

Yoshiko Atsuta (Y)

Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.

Norbert Gattermann (N)

Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.

Benjamin L Ebert (BL)

Department of Medical Oncology and Howard Hughes Medical Institute, Dana-Farber Cancer Center, Boston, MA, USA.

Rafael Bejar (R)

UC San Diego Moores Cancer Center, La Jolla, CA, USA.

Peter L Greenberg (PL)

Stanford University Cancer Institute, Stanford, CA, USA.

Mario Cazzola (M)

Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Department of Hematology, IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy.

Eva Hellström-Lindberg (E)

Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.

Elli Papaemmanuil (E)

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. papaemme@mskcc.org.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. papaemme@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH